U.S. Markets open in 18 mins

Free Technical Reports on MannKind and Three Additional Biotech Equities

Stock Research Monitor: LXRX, MRNS, and NEPT

LONDON, UK / ACCESSWIRE / June 15, 2018/ If you want a free Stock Review on MNKD sign up now at www.wallstequities.com/registration. This morning, WallStEquities.com is focused on the Biotech space, which is engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Under evaluation today are these four equities: Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), MannKind Corp. (NASDAQ: MNKD), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT). All you have to do is sign up today for this free limited time offer by clicking the link below.


Lexicon Pharmaceuticals

On Thursday, shares in The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc. rose slightly by 0.86%, ending the day at $12.89. The stock recorded a trading volume of 617,080 shares, which was above its three months average volume of 600,620 shares. The Company's shares have advanced 31.40% in the last month and 52.18% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 33.68% and 26.31%, respectively. Moreover, shares of Lexicon Pharma, which focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases, have a Relative Strength Index (RSI) of 78.34. Get the full research report on LXRX for free by clicking below at:



Shares in Westlake Village, California headquartered MannKind Corp. ended the day 2.07% lower at $1.89 with a total trading volume of 1.74 million shares. In the last month and over the past year, the stock has gained 0.53% and 38.97%, respectively. The Company's shares are trading above their 50-day moving average by 2.58%. Furthermore, shares of MannKind, which focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients, have an RSI of 49.15.

On June 07th, 2018, MannKind announced that it has completed a Phase-1 clinical study of Treprostinil Technosphere (TreT) under an Investigational New Drug application filed with the FDA. Based on these data, the Company is preparing the next phase of development to evaluate the safety and tolerability of TreT in patients with PAH. Today's complimentary research report on MNKD is accessible at:


Marinus Pharmaceuticals

At the close of trading on Thursday, shares in Radnor, Pennsylvania-based Marinus Pharmaceuticals Inc. finished 1.24% higher at $7.35 with a total trading volume of 601,328 shares. The stock has surged 54.41% in the last month, 74.58% over the previous three months, and 478.74% over the past year. The Company's shares are trading above their 50-day and 200-day moving averages by 39.66% and 27.22%, respectively. Additionally, shares of Marinus Pharma, which focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders, have an RSI of 68.74.

On May 30th, 2018, Marinus Pharma announced that Christopher M. Cashman, President and CEO, will present a Company overview and host investor meetings at the JMP Securities Life Sciences Conference on June 20th, 2018, at 10:30 a.m. ET at the St. Regis New York in New York. A live webcast of the presentation may be accessed on the Company's website. Register now for your free research document on MRNS at:


Neptune Technologies & Bioressources

Laval, Canada headquartered Neptune Technologies & Bioressources Inc.'s shares recorded a trading volume of 387,188 shares at the end of yesterday's session, which was above their three months average volume of 354,890 shares. The stock closed the day 3.39% higher at $2.44. The Company's shares have skyrocketed 156.84% over the past year. The stock is trading above its 200-day moving average by 14.06%. Additionally, shares of the Company, which focuses on providing nutrition solutions, including specialty ingredients and consumer brands, have an RSI of 32.67.

On June 05th, 2018, Neptune Technologies & Bioressources announced its results for the three-month and 12-month periods ended March 31st, 2018. For Q4 2018, revenues were C$7.0 million, and net loss was C$4.8 million. For the year end, revenues were C$26.2 million, and net income was C$20.1 million. Click on the link below and see our free report NEPT at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities